PD-1 억제제 Cemiplimab을 이용한 신보조 요법(Tx)으로 치료하는 메르켈 세포 암종 (NeoMatryx)
PD-1 억제제 세미플리맙을 이용한 네오어드주반트 머켈 세포 암종 치료(Tx) - 무작위, 이중 맹검, 위약 대조, 비비교적 2상 연구
The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph node biopsy.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Michelle Tez
- 이메일: tez.michelle@ikf-khnw.de
연구 연락처 백업
- 이름: Ralf Gutzmer, Prof. Dr. med.
- 이메일: Ralf.Gutzmer@Muehlenkreiskliniken.de
연구 장소
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, 독일, 69120
- 모병
- Nationales Centrum für Tumorerkrankungen
-
연락하다:
- Jessica Hassel, Prof. Dr.
-
Mannheim, Baden-Wurttemberg, 독일, 68161
- 모병
- Universitätsklinikum Mannheim
-
연락하다:
- Jochen Utikal, Prof. Dr.
-
Tübingen, Baden-Wurttemberg, 독일, 72076
- 모병
- Universitätsklinikum Tübingen
-
연락하다:
- Ulrike Leiter-Stöppke, Prof. Dr.
-
-
Bavaria
-
Regensburg, Bavaria, 독일, 93053
- 모병
- Universitätsklinikum Regensburg
-
연락하다:
- Sebastian Haferkamp, Prof. Dr.
-
Würzburg, Bavaria, 독일, 97080
- 모병
- Universitätsklinikum Würzburg
-
연락하다:
- Anja Gieserich, Dr.
-
-
Free and Hanseatic City of Hamburg
-
Hamburg, Free and Hanseatic City of Hamburg, 독일, 20246
- 모병
- Universitätsklinikum Hamburg-Eppendorf
-
연락하다:
- Christoffer Gebhardt, Prof. Dr.
-
-
Hesse
-
Frankfurt am Main, Hesse, 독일, 60590
- 모병
- Universitätsklinikum Frankfurt
-
연락하다:
- Bastian Schilling, Prof. Dr.
-
-
North Rhine-Westphalia
-
Bielefeld, North Rhine-Westphalia, 독일, 33647
- 모병
- Klinikum Bielefeld
-
연락하다:
- Selma Ugurel, Prof. Dr.
-
Essen, North Rhine-Westphalia, 독일, 45147
- 모병
- Universitätsklinikum Essen
-
연락하다:
- Dirk Schadendorf, Prof. Dr.
-
Minden, North Rhine-Westphalia, 독일, 32429
- 아직 모집하지 않음
- Johannes Wesling Klinikum Minden
-
연락하다:
- Ralf Gutzmer, Prof. Dr.
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, 독일, 55131
- 모병
- Universitätsmedizin Mainz
-
연락하다:
- Stefan Grabbe, Prof. Dr.
-
-
Thuringia
-
Erfurt, Thuringia, 독일, 99089
- 모병
- Helios Klinikum Erfurt
-
연락하다:
- Rudolph Herbst, Prof. Dr.
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion criteria
-
Patient has signed informed written consent.
-
Patients is 18 years and older at time of signing of written informed consent
-
Patient has diagnosis of Merkel cell carcinoma in clinical stage II, or in stage I with minimum diameter of 1 cm, with primary tumor already removed and a planned sentinel lymph nodes biopsy still pending.
-
Patient has ECOG performance status 0-2.
-
Patients has adequate laboratory parameters particularly for the blood count, renal and liver function parameters.
- Absolute number of neutrophils ≥ 1.5 x 109/L
- Platelets ≥ 75 x 109/L
- Hemoglobin ≥ 9 g/dL
- Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) (patients with Gilbert´s Disease and total bilirubin up to 3x ULN may be eligible after approval from trial's medical expert)
- AST (SGOT) and ALT (SGPT) ≤ 3x ULN
- AP ≤ 2.5x ULN
- Serum creatinine ≤ 2x ULN or creatinine clearance ≥ 40 mL/min
-
Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 6 months after the last dose of Cemiplimab. Male patients must refrain from donating sperm during this same period. Male patients with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy.
-
Patient must be willing to allow translational work-up of tissue samples (PT, sentinel lymph node biopsy).
Exclusion criteria
-
Patient has prior sentinel lymph node removal for the current MCC.
-
Patients received prior treatment with immunotherapy (such as PD-1/PD-L1 or CTL4) or any other systemic anti-tumor (MCC) therapy (incl. investigational therapies)
-
Patient has active or a history of hematological neoplasms including chronic lymphocytic leukemia (CLL), irrespective if these require treatment or not.
-
Patient had prior organ transplantation including allogenic stem-cell transplantation.
-
Patient receives immunosuppressive concomitant medication, EXCEPT for the following:
i. Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection).
ii. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent.
iii. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
-
Patient has known hypersensitivity to any component of the Cemiplimab formulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein.
-
Patient has active autoimmune or inflammatory disorders.
-
Patient has history of interstitial lung disease.
-
Patient has active infection requiring systemic therapy.
-
Patient has Active infection requiring systemic therapy, including uncontrolled HIV, HBV and HCV infection or diagnosis of immunodeficiency.
NOTE: Patients are eligible if:
- Patients have controlled HIV infection with CD4 counts is > 350 cells/μL and viral load is undetectable [HIV RNA PCR]. Patients with controlled HIV infection must be monitored per local standards during the trial.
- Patients positive for HBV surface antigen have controlled HBV infection receiving anti-viral therapy and with undetectable serum viral load [HBV DNA PCR]. Patients with controlled infection must undergo periodic monitoring of HBV DNA and p must remain on anti-viral therapy for at least 6 months after last dose of Cemiplimab.
- Patients positive for HCV antibody have controlled HCV infection with undetectable viral load [HCV RNA PCR].
-
Patent received vaccination with any live vaccine (e.g., intranasal flu vaccine) within 4 weeks before the first dose of Cemiplimab or planned vaccination with live vaccine during the trial
-
Female patients, who are pregnant or breast feeding or planning to become pregnant within and 6 months after the end of treatment. Female patients of childbearing potential must have a negative serum β-HCG pregnancy test result within 7 days prior to initiation of study treatment.
-
Patient has evidence of any other disease, neurologic or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any of the study medications, puts the patient at higher risk for treatment-related complications or may affect the interpretation of study results.
-
Patient has known substance abuse or other psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
-
Patient is legally incapacitated or has limited legal capacity
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Arm A (Cemiplimab)
2 cycles of Cemiplimab (350 mg, i.v., Q3W) followed by sentinel lymph node biopsy |
Patients will receive Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles
다른 이름들:
|
|
위약 비교기: Arm B (placebo)
2 cycles of placebo followed by sentinel lymph node biopsy |
Patients will receive NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Nodal micrometastases-free rate
기간: up to 36 months
|
rate of patients without nodal micrometastases after 2 cycles of treatment, determined by sentinel lymph node biopsy |
up to 36 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Recurrence-free survival
기간: up to 66 months
|
time from randomization until date of the first of the following events: MCC recurrence, and MCC-related death |
up to 66 months
|
|
Time to recurrence
기간: up to 66 months
|
defined as time from randomization until date of first MCC recurrence |
up to 66 months
|
|
Overall survival
기간: up to 66 months
|
time from randomization until date of death from any cause |
up to 66 months
|
|
Quality of life using FCRI-SF questionnaire
기간: up to 66 months
|
Quality of life determined using the FCRI-SF questionnaire |
up to 66 months
|
|
Safety (AEs and SAEs)
기간: up to 66 months
|
incidence, nature, causality, frequency, timing and severity of adverse events using NCI CTCAE 5 |
up to 66 months
|
|
Disease specific survival
기간: up to 66 months
|
time from randomization until date of MCC-related death |
up to 66 months
|
|
Quality of life using the mFACT-M questionnaire
기간: up to 66 months
|
Quality of life determined using the mFACT-M questionnaire |
up to 66 months
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Investigation of prognostic and predictive biomarkers to estimate the risk of lymph node metastases and signs of immune activation in the sentinel lymph nodes
기간: up to 66 months
|
Biosamples will be used to determine the correlation of identified biomarkers with clinical outcome, i.e., nodal metastases-free rate, RFS, OS |
up to 66 months
|
공동 작업자 및 조사자
스폰서
스폰서
협력자
협력자
수사관
수사관
- 연구 책임자: Salah Al-Batran, Prof. Dr., Institut für Klinische Krebsforschung IKF GmbH
- 수석 연구원: Ralf Gutzmer, Prof. Dr. med., Johannes Wesling Klinikum Minden
- 수석 연구원: Juergen C. Becker, Prof. Dr. Dr., Translational Skin Cancer Research University Duisburg-Essen, Germany
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- NeoMatryx
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .